01Why this case belongs in the series — the question of a duty to disclose
Most drug disasters in this series begin with something that was not yet known. The teratogenicity of thalidomide, the neurotoxicity of clioquinol in the SMON disaster — at the outset, neither regulators nor companies understood the mechanism of harm. The hepatitis C incident is different at its core.
The Ministry of Health (now the Ministry of Health, Labour and Welfare, or MHLW) held manufacturing and distribution records for fibrinogen concentrate. The producing companies knew which hospitals had received which lots. The information existed. It simply never reached the patients who needed it. This is not a failure of knowledge — it is a failure of disclosure.
The question this case forces into focus is one of the deepest in pharmaceutical governance: when a public authority holds information that could tell an individual she may have been harmed by a drug, does it have a legal and ethical duty to tell her? Japan's answer, legislated in 2008, was yes — but that answer came only after roughly 10,000 people had been infected.
02Fibrinogen concentrate — and why pooled plasma carries unique risk
Fibrinogen is the protein that anchors the final step of the clotting cascade. When a blood vessel is damaged, thrombin converts fibrinogen to fibrin, the mesh that forms a clot and halts bleeding. During surgery or postpartum hemorrhage — the life-threatening bleeding that can follow childbirth — intravenous fibrinogen concentrate was, through the 1970s and into the 1990s, one of the standard tools Japanese obstetricians and surgeons reached for.
In Japan, fibrinogen concentrate was approved in 1964 and rapidly adopted in obstetrics and surgery. The principal manufacturer was Midori Juji Co., Ltd. (Green Cross Corporation; later absorbed into Mitsubishi Pharma and then Mitsubishi Tanabe Pharma); Benesis Corporation also manufactured the product. Raw plasma was largely imported from the United States.
031977 — the U.S. FDA revokes approval; Japan does not follow
In 1977, the U.S. Food and Drug Administration revoked its approval of fibrinogen concentrate. The reasoning was explicit: the risk of hepatitis B virus (HBV) transmission was unacceptably high, and the evidence of clinical benefit was insufficient to justify that risk. Hepatitis C virus (HCV) had not yet been identified — it would be isolated only in 1989 — but post-transfusion hepatitis caused by what was then called "non-A, non-B hepatitis virus" was already well documented in clinical literature, and fibrinogen concentrate was recognized as a primary transmission route.
That FDA decision was reported to Japan's Ministry of Health. Japan did not revoke its own approval. There was genuine clinical demand — postpartum hemorrhage and surgical bleeding are immediately life-threatening, and alternative hemostats were not yet widely established. But the deeper institutional failure was structural: there was no mechanism that treated a foreign regulator's safety action as a mandatory trigger for domestic review. A major trading partner's drug authority had pulled the product; Japan's ministry noted it and moved on.
04The 1980s — restricted use warned but not enforced
By the early 1980s, the problem of post-transfusion hepatitis had become harder to ignore. Cases linked to blood products were multiplying in Japan and abroad. In 1988 the Ministry of Health issued guidance to obstetrics and surgery associations urging "appropriate use" of fibrinogen concentrate — meaning doctors should limit it to cases where other options had failed.
That guidance stopped well short of a sales suspension. The instruction passed to individual hospitals was essentially "use it only when necessary," with the judgment of necessity left to each clinical team. The product remained on the market.
Sales of fibrinogen concentrate were finally halted in 1994. But product already held as hospital inventory continued to be administered for some time after that. The timeline of harm extended past the official discontinuation date.
052002–2007 — class-action lawsuits and the records that spoke
The full scale of the disaster came into view through litigation. Beginning in 2002, patients diagnosed with chronic hepatitis C began tracing the origin of their infection. Reviewing decades-old hospital charts, some found administration records for fibrinogen concentrate that aligned precisely with their estimated date of infection. The pattern was unmistakable.
From 2002, coordinated lawsuits were filed in district courts across Japan — Osaka, Tokyo, Fukuoka, Nagoya, and others. Plaintiffs named both the state and the successor companies of Midori Juji as defendants, arguing delayed warning, defective product, and inadequate safety oversight. Over five years, district and appellate courts issued a series of rulings that went substantially in the plaintiffs' favor.
"I found out that the drug I was given on the day I gave birth was what infected me with hepatitis C — more than twenty years after the fact. For all that time I had been living without knowing what had happened to me, or why." — plaintiff testimony, as reported in court records
The litigation built a detailed documentary record: internal company documents showing awareness of hepatitis transmission risk, ministry correspondence confirming that warnings had been considered but moderated, and distribution logs tracing specific lots to specific hospitals. What had been scattered knowledge became evidence.
062007 — the disclosure of the 7,000-patient list
In 2007, parliamentary questioning revealed what became the defining fact of the entire affair. The MHLW had held detailed records — compiled from manufacturing lot-management data and hospital distribution logs submitted by the producing companies — covering approximately 7,000 patients who had received the implicated products. The records in many cases included names, addresses, and dosing information sufficient to allow direct individual contact. No one had been notified.
The ministry offered several explanations: personal information protection constraints, a preference for notification through treating physicians, and the administrative complexity of contacting individuals across institutions and decades. Victims' groups and the plaintiff attorneys rejected every rationale.
The revelation of the list broke the legal stalemate. Parliamentary committees focused sustained attention on the MHLW's conduct, and the legislative machinery that produced the 2008 relief act moved with unusual speed by Japanese standards.
072008 — the Drug-induced Hepatitis Relief Act and no-fault compensation
In January 2008, the Act on Special Measures Concerning Payment of Benefits to Victims of Hepatitis C Infection through Specific Fibrinogen Products and Specific Blood Coagulation Factor IX Complex Products — commonly called the Yakugai Kanen Kyusai-ho (Drug-induced Hepatitis Relief Act) — was enacted. The bill passed both houses of the Diet unanimously, an outcome rare enough in Japanese parliamentary history to signal genuine cross-party consensus. It entered into force on January 16, 2008.
| Feature | What the Relief Act established |
|---|---|
| Covered products | Specified fibrinogen concentrates (including those manufactured by Midori Juji / Green Cross) and specified Factor IX complex products |
| Who is covered | Individuals infected with HCV through those products, including surviving family of deceased victims |
| Benefit tiers | Differentiated by disease stage — liver cirrhosis or liver cancer / chronic hepatitis / asymptomatic carrier — up to ¥40 million per person |
| Causation standard | Administration record alone is sufficient to presume causation — plaintiffs are not required to prove it independently |
| Funding | Shared between the national government and the manufacturing companies |
| Statute of limitations | Extended by special provision to allow claims that would otherwise have been time-barred |
The act's central innovation was its approach to causation. Standard tort litigation places the burden of proving a causal link between product and injury on the plaintiff — a burden that, across two or three decades of elapsed time, is often impossible to meet. The Relief Act reversed that: an administration record creates a legal presumption of causation, and the state pays without requiring further proof. This brought the hepatitis case into the same policy lineage as the drug-induced AIDS settlement of the mid-1990s — the accumulated recognition that injured patients should not be left to carry the evidentiary burden of systemic institutional failure.
08Regulatory consequences — tightening the rules for biologics
The policy response did not end with the relief fund. Amendments to Japan's Pharmaceutical Affairs Act (now the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, PSEHB Act / Yakki-ho) substantially tightened oversight of biological products, building on groundwork laid in a 2003 amendment and reinforced after 2008.
- Explicit classification of biological products: Blood products, cell therapies, and related materials are designated as "biological products" (seibutsu yurai seihin) carrying enhanced manufacturing, quality-management, and lot-traceability obligations distinct from standard pharmaceuticals
- Mandatory nucleic acid amplification testing (NAT) for donor plasma: All imported source plasma must be screened for HCV, HBV, and HIV by NAT; a single reactive donation triggers rejection of the entire pool lot
- Mandatory look-back programs: If a donor is subsequently found to have been infectious at the time of donation, manufacturers and the PMDA (Pharmaceuticals and Medical Devices Agency) must trace all products derived from that donor's plasma and notify the receiving patients — precisely the process that did not happen with the 7,000-person list
- PMDA international safety signal sharing: Formal procedures require the PMDA to monitor and respond to safety actions taken by the FDA, EMA, and other major regulators — closing the institutional gap that allowed the 1977 FDA revocation to pass without triggering Japanese action
09Four lessons that carry forward
Lesson 1 — Holding information is not the same as using it
The 7,000-patient list existed. The addresses were on file. What failed was not data management — it was the institutional will to act on the data. Regulators and companies that accumulate safety information have an obligation to deploy it toward patient protection, not merely to archive it. The post-2008 look-back mandate converted that moral obligation into statute. For anyone working in pharmacovigilance today, this case is the clearest possible argument against treating adverse-event databases as compliance artifacts rather than active patient-protection tools.
Lesson 2 — Pooled biological products carry a fundamentally different risk profile
A synthetic small-molecule drug is a uniform chemical compound. Plasma-derived biologics are made from the blood of thousands of donors merged into a single lot. One infectious donor can expose every patient who receives product from that lot. The scale of potential harm from a single contamination event in a pooled product has no equivalent in conventional pharmaceuticals. This structural feature makes stringent donor screening, lot traceability, and look-back capability not luxuries but prerequisites. The same logic — amplified by even greater complexity — applies to modern gene therapies and CAR-T cell products.
Lesson 3 — No-fault relief frameworks are the realistic path to justice for systemic harm
Had every hepatitis C victim been required to pursue individual tort litigation, most would never have received compensation. Proving a causal chain spanning twenty or thirty years, across hospitals that may no longer exist, through records that may have been lost, is beyond the practical capacity of most patients. The presumption-of-causation approach embedded in the 2008 act — if you have an administration record, you are covered — reflects a policy judgment that when a harm is systemic and the evidence asymmetry is this severe, the state must bear the burden, not the patient. The drug-induced AIDS settlement of 1996 established the precedent; the hepatitis act extended it.
Lesson 4 — A foreign regulator's safety action is a signal, not a foreign-affairs matter
The FDA revoked fibrinogen concentrate in 1977. Japan's ministry was informed. The information was not treated as a mandatory safety trigger. Had Japan matched the FDA's action at that point, a substantial portion of the infections that accumulated through the 1980s and into the 1990s would not have occurred. In a world where plasma is globally traded and product lots cross borders, a major foreign regulator's withdrawal of approval for a class of biological product is a direct signal requiring domestic response — not a diplomatic data point to be noted and filed. The PMDA's international coordination mandate, strengthened after 2008, is the institutional response to that lesson.
10Connections to other chapters
- Drug Disasters 02 — Thalidomide: Both cases involve regulatory lag after a foreign authority acted; thalidomide's structural failure was absent safety testing, hepatitis C's was absent regulatory follow-through on international signals — different failure modes, same pattern of preventable delay
- Drug Disasters 05 — Drug-induced AIDS: The immediately preceding chapter. Both involve plasma-derived products and Midori Juji / Green Cross; the 1996 AIDS settlement's no-fault compensation precedent directly shaped the 2008 hepatitis act
- Compliance Vol. 1: The duty of entities that hold safety information to act on it is a central governance principle — this case provides its sharpest real-world illustration
- Ethics Vol. 3: The right of patients to be informed of risks to their own health — informed consent's broader cousin — is directly at issue when a ministry holds a list and stays silent
The government knew the names. It held addresses for roughly 7,000 people who had received the implicated product. It did not contact them. That silence lasted years.
Every drug disaster in this series has involved something that was unknown — a hidden toxicity, an unrecognized virus, a mechanism of harm that science had not yet mapped. This case is unique because the harm was known, the patients were identifiable, and the decision not to reach them was made inside institutions that held the information.
"Does an authority that holds safety information have a duty to use it for the patient's benefit?" It took tens of thousands of infections, years of litigation, and a parliamentary confrontation over a list of 7,000 names to produce a clear legal answer: yes. The 2008 Relief Act and the look-back mandate wrote that answer into statute.
But statutes are activated only by the people inside institutions who choose to enforce them. For anyone in pharmaceutical development, regulatory affairs, or pharmacovigilance today, the hepatitis C case carries a single irreducible message: when you hold safety information about patients, the default is disclosure — not silence.